Travere Therapeutics Inc Q3 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Will Soghikian - Leerink Partners LLC - Analyst : This is Will on for Joe today. Congrats on the great quarter here. So just one for us on PSF metrics. We saw that very minor dip in numbers between the second and third quarter. And as Peter mentioned, it seems like this could be chalked up to summer seasonality and taking the sales force out for a week in September. But are there other dynamics here that we should appreciate? And how have things been trending now early in the fourth quarter? Any additional color here would be helpful.

Question: Arseniy Shabashvili - Guggenheim Securities, LLC - Analyst : It's Arseniy for Vamil. Congrats on all your progress and thank you for taking our questions. In regard to PARASOL recommendations and FSGS, how much do you feel the discussions with the FDA will focus on hitting specific proteinuria's thresholds at certain time points? And perhaps reanalyzing the data that way versus considering the totality of data more holistically and focusing more on the mechanistic rationale and the biological visibility argument?

Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst : Congrats on all the progress at ASN and in the quarter. Can you give us a sense of the scope of the additional data you've provided on liver monitoring sort of beyond the clinical experience? I'm assuming that package includes all of the data from FSGS and IgAN again, clinical trial work, but correct me if I'm wrong there?

Question: Farzin Haque - Jefferies LLC - Analyst : This is Farzin on for Maurie. Congrats on the progress as well. Following up on the FSGS Type C meeting, are you going to include any data from the open label extension? And then do you also on the post hoc analysis, like what would be considered like sufficient? Like is the pre-specified data already good enough or any post hoc work would be needed? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 31, 2024 / 12:30PM, TVTX.OQ - Q3 2024 Travere Therapeutics Inc Earnings Call

Question: Farzin Haque - Jefferies LLC - Analyst : Yes. Thank you, Bill. And I'll point you all to our corporate presentation which is posted on our website. If you look at slide 29, you can see very nicely laid out the treatment effect across those different pre-specified thresholds, clearly showing a benefit and superiority for sparsentan over irbesartan and FSGS. Thanks, Bill.

Question: Joe Thomas - Scotia Capital Inc. - Analyst : Congrats on the quarter. This is Joe Thomas on for Greg, just one kind of on the patient and physician education front, can you maybe comment on any ongoing efforts or opportunities you might have to help patients be getting diagnosed earlier and treated earlier based on the recent KDIGO draft guideline update?

Question: Laura Chico - Wedbush Securities, Inc. - Analyst : I had one on FSGS. There was some commentary at the PARASOL meeting earlier this month and just coming out of ASN now, I'm wondering if you have any thoughts on whether groups like KDIGO would consider making an update to FSGS treatment guidelines in response to the observational data that PARASOL presented.

Question: Charles Ndiaye - Stifel, Nicolaus & Company, Inc. - Analyst : This is Charles Ndiaye on for Alex. Congrats on all the progress this quarter. I guess from our end just wanted to ask about your current expectations for LOE in IgAN and how you see those changing in the near future?

Question: Arseniy Shabashvili - Guggenheim Securities, LLC - Analyst : It's Arseniy on for Vamil. In regards to FILSPARI's IgAN launch, could you comment on your feel for the uptake with community based nephrologists versus academic thought leaders now versus when you first launched? In other words, do you feel that your message is getting out to a broader group of nephrologists now?